Bisphosphonates

被引：55

作者：

McClung, MR

机构：

[1] Providence Portland Med Ctr, Dept Med Educ, Portland, OR 97213 USA

[2] Providence Portland Med Ctr, Oregon Osteoporosis Ctr, Portland, OR 97213 USA

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2003年 / 32卷 / 01期

关键词：

D O I：

10.1016/S0889-8529(02)00079-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bisphosphonates now occupy a prominent position among therapeutic options for the prevention and treatment of various forms of osteoporosis. Their clinical profile of bone-specific efficacy, rapid response, protection from both spine and hip fractures in patients with osteoporosis, and excellent tolerability is all that should be expected of an anti-remodeling drug. Even in the era of anabolic agents, bisphosphonates will continue to be important treatment options.

引用

收藏

页码：253 / +

页数：20

相关论文

共 114 条

[1]

Abraham SC, 1999, MODERN PATHOL, V12, P1152

[2] Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis [J].

Adachi, JD ;

Bensen, WG ;

Brown, J ;

Hanley, D ;

Hodsman, A ;

Josse, R ;

Kendler, DL ;

Lentle, B ;

Olszynski, W ;

SteMarie, LG ;

Tenenhouse, A ;

Chines, AA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :382-387

[3]

Adachi JD, 2001, ARTHRITIS RHEUM-US, V44, P202, DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO

[4]

2-W

[5] Tolerability of risedronate in postmenopausal women intolerant of alendronate [J].

Adachi, JD ;

Adami, S ;

Miller, PD ;

Olszynski, WP ;

Kendler, DL ;

Silverman, SL ;

Licata, AA ;

Li, Z ;

Gomez-Panzani, E .

AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2001, 13 (05) :347-354

[6] THE ACUTE-PHASE RESPONSE AFTER BISPHOSPHONATE ADMINISTRATION [J].

ADAMI, S ;

BHALLA, AK ;

DORIZZI, R ;

MONTESANTI, F ;

ROSINI, S ;

SALVAGNO, G ;

LOCASCIO, V .

CALCIFIED TISSUE INTERNATIONAL, 1987, 41 (06) :326-331

[7] Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta [J].

Åström, E ;

Söderhäll, S .

ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 86 (05) :356-364

[8] Upper gastrointestinal tract safety profile of alendronate -: The Fracture Intervention Trial [J].

Bauer, DC ;

Black, D ;

Ensrud, K ;

Thompson, D ;

Hochberg, M ;

Nevitt, M ;

Musliner, T ;

Freedholm, D .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (04) :517-525

[9] Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women [J].

Bell, NH ;

Bilezikian, JP ;

Bone, HG ;

Kaur, A ;

Maragoto, A ;

Santora, AC .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (06) :2792-2797

[10] Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates:: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs [J].

Benford, HL ;

Frith, JC ;

Auriola, S ;

Mönkkönen, J ;

Rogers, MJ .

MOLECULAR PHARMACOLOGY, 1999, 56 (01) :131-140

← 1 2 3 4 5 6 7 8 9 10 →